

# BANTWAL SURESH BALIGA, M.D., M.R.C.P. (U.K.)

320 SKYWAY DRIVE, SUITE 602  
OPELIKA, AL 36801  
TELEPHONE- 334-737-2737  
FAX- 334-821-1043  
Email: bantwal@yahoo.com

---

## EMPLOYMENT HISTORY:

**January 2009 – Present** Director: East  
Alabama Endocrinology, P.C.  
3320 Skyway Drive, Suite 602  
Opelika, AL 36801

**September 2005–January 2009** Endocrine  
Consultants, P.C. 2425 Brookstone Centre  
Parkway  
Columbus, GA 31904

**August 2001– August 2005** Assistant  
Professor, Mt. Sinai School of Medicine New  
York, NY

---

## ACADEMIC APPOINTMENTS:

**2012– 2016** Chief, Division of Endocrinology  
The Columbus Regional Medical Center  
Columbus, GA

**January 2004–August 2005** Chief, Division of  
Endocrinology & Metabolism North General  
Hospital  
New York, NY

**August 2001–August 2005** Director, Clinical  
Diabetes Program  
Assistant Professor, Division of Endocrinology  
Assistant Professor, Division of Diabetes &  
Aging Mt. Sinai School of Medicine  
New York, NY

**August 2001–June 2002** Staff Physician,  
Endocrinology Division Veterans Hospital, Bronx  
New York, NY

**October 1998–July 2001** Staff Physician,  
Primary Care Division  
Veterans Hospital Little Rock, AR

**March 2001–July 2001** Assistant Professor in  
Medicine  
University of Arkansas for Medical Sciences  
Little Rock, AR

---

## ACADEMIC APPOINTMENTS:

**January 1986–December 1990** Chief Physician  
Alva's Health Center Moodbidri, India

---

## EDUCATION:

**1975–1976** Bachelor of Science  
SVS College  
Bantwal, India

**1976–1985** Kasturba Medical College  
Mangalore, India, Received MBBS

**1982–1985** Kasturba Medical College  
Mangalore, India, Received MD (Internal Medicine)

---

## POSTDOCTORAL TRAINING:

**June 1996–May 1998** Internal Medicine Residency  
University of Arkansas for Medical Sciences Little Rock,  
Arkansas

**July 1995–June 1996** Clinical Fellow, Endocrinology  
University of Arkansas for Medical Sciences Little Rock,  
Arkansas

**June 1993–June 1995** Registrar in General Medicine,  
Diabetes, & Endocrinology, and Geriatrics Royal Liverpool  
University Hospital & Arrowe Park Hospital  
United Kingdom

**August 1991–May 1993** SHO in General Medicine, Acute  
geriatric Medicine East Glamorgan General Hospital  
Mid Glamorgan, UK

**July 1982–May 1985** Resident Registrar in Medicine  
Kasturba Medical College Mangalore, India

**May 1981–April 1982** Rotating Housemanship in Medicine,  
Surgery, Obstetrics, & Gynecology  
Kasturba Medical College Mangalore, India

## CURRICULUM VITAE

**BANTWAL SURESH  
BALIGA, M.D.,  
M.R.C.P. (U.K.)**

---

### CERTIFICATION:

**2006** Board Certification in endocrinology, diabetes, & Endocrinology USA

**1998** Board Certification in Internal Medicine USA

**1993 M.R.C.P. (U.K.)** February 25, 1993  
Royal College of Physicians & Surgeons

**1985 M.D.** (Internal Medicine) Post Graduate  
Diploma Kasturba Medical College  
Mangalore, India

---

### LICENSURE:

**March 2006** State of Alabama Active

**August 2005** State of Georgia Active

**September 2001** State of New York Inactive

**March 1998** State of Arkansas Inactive

---

### HONORS, AWARDS, PATENTS:

**1975** National Merit Scholarship Awarded by Government of India

---

### OTHER PROFESSIONAL APPOINTMENTS:

Member, Advisory Committee on Clinical Guidelines, 1999 VA Hospital  
Little Rock, AK

Member, Clinical Initiative Committee Mt. Sinai School of Medicine  
New York, NY

---

### INDUSTRY RELATIONS:

Ex-Consultant, Pfizer Advisory Board

Ex Member, Speakers Bureau GSK

Member, Speakers Bureau AstraZeneca

Member, Speakers Bureau Boehringer- Ingelheim Pharmaceuticals

Member, Speakers Bureau Novo Nordisk

Member, Speakers Bureau Astrazeneca

Ex Member, Speakers Bureau Amarin Pharmaceuticals

Member, Speakers Bureau Abbott

Member, Speakers Bureau Senseonics

Member, Advisory Board Ascencia

Member, Advisory Board Senseonics

Member, Advisory Board Bigfoot Biomedical

---

### TRAINING RECORD:

I have trained nurse practitioners in the recent past, in addition to several residents and Endocrine Fellows.

---

### TEACHING ACTIVITIES:

**1982 – 1985** During post-grad training, I taught under-grad students of Kasturba Medical College on a daily basis (lectures and bedside teaching)

**1991 –1995** Taught post-grad students appearing for membership, nurses and nurse practitioners in U.K. (lectures, bedside teachings, and mock clinical exams)

**1995– 2001** Taught students, residents, and fellows at University of Arkansas for Medical Sciences, Little Rock, AR.

**2001– 2005** Taught students, residents, and fellows at Mt. Sinai School of Medicine, New York, NY

**2009–Current** Training Residents from Family Practice Residency Program– The Piedmont Medical Center, Columbus, GA

**2022–Current** Training Residents from Internal Residency Program, St Francis Hospital, Columbus, GA

## CURRICULUM VITAE

**BANTWAL SURESH  
BALIGA, M.D.,  
M.R.C.P. (U.K.)**

---

### GRANT SUPPORT:

Glaxo-SmithKline Award – \$50,000 x 2 years.  
2001 to 2012 . Mt Sinai Hospital, New York, NY

---

### RESEARCH ACTIVITIES:

Dietary Glycotoxins: Effect of Low AGE diet on AGE turnover and markers of vascular dysfunction. (GCO#99- 0467-P.I.)

The major goal of the research is to determine the feasibility of AGE restriction using a well-balanced and palatable diet in improving glycemic control and endothelial dysfunction.

Effect of Low AGE diet and/or thiazolidinediones on a AGE turnover, insulin resistance, glycemic control and markers of endothelial dysfunction. (GCO#02-0417 P.I.)  
The major Goal of the research is to determine the feasibility of AGE restriction using a well-balanced and palatable diet and also to see the effect of thiazolidinediones on the glycemic control.

Pilot evaluation of the efficacy of a diet low in AGE to prolong the honeymoon period of T1D. IRB approved GCO # 02-0417 (P.I.) The major goal of this research is to see whether placing new onset type 1 diabetics on low AGE diet will prolong their honeymoon period.

---

### RESEARCH ACTIVITIES:

Efficacy and Safety of Inhaled Technosphere/Insulin Compared to Technosphere/placebo in Patients with Type 2 Diabetes Mellitus Follow Diabetes Education. (P.I) Sponsored by PDC Pharmaceuticals. Submitted to IRB recently.

A Trial of Insulin-Sensitivity Enhancing Agent to Improve Cognitive Outcome in Alzheimer's disease. (S.I.)

The major goal is to see whether insulin sensitizing agent metformin can improve cognitive outcome in Alzheimer's disease.

"Risk Factors in Very Late Onset AD" GCO # 84-119 (S.I.)

The major goal is to see whether insulin resistance and advance glycation end products predict the onset of Alzheimer's Disease.

A Multicenter, Double-Blind, Placebo controlled, Randomized Study of the Safety of TAK – 559 in the Treatment of Patients with Type 2 Diabetes Mellitus (P.I.) Sponsor: Takeda Pharmaceuticals of North America

Periscope Study: A Double Blind, Randomized, Comparator-controlled Study in Subjects with Type2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCL versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultrasound (P.I.)

A Multicenter, Randomized, Double Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 2 weeks in Subjects with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Insulin (P.I)

Efficacy and Safety of Inhaled Human Insulin (Exubra) Compared to Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A One-Year, Multicenter, Randomized, outpatient, Open-Label, parallel- Group Comparative Trial, (P.I)

Clinical Trial on Pulsatile Intra-Venous Insulin Therapy, 2011-2015

CEP 266: Post Approval Study of the TS (Threshold-Suspend) Feature With A Sensor-Augmented Pump System 2015

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes

- November 2020
  - BMJ Open Diabetes Research & Care 8(2):e001832
- Authors: Pablo Mora, David R Sutton, Adhwini Gore, Bantwal Baliga

The Burst Study: Bigfoot Unity Real World Study: Study Protocol 21 BFO1 : Ongoing: Objective: The study objective is to collect real-world data from Bigfoot Unity in approximately 150 participants.

## CURRICULUM VITAE

**BANTWAL SURESH  
BALIGA, M.D.,  
M.R.C.P. (U.K.)**

---

### PUBLICATIONS:

1. Fonseca V., Munshi, M. **Baliga, B.S.**, Stone, A., Fink, L., Dandona, P. Oxidative stress in Diabetic Macro-vascular Disease: Does homocysteine play a role? Southern Med J 1997, 90:903-906
2. **Baliga, B.S.**, Tammy Reynolds, Louise M. Fink, and Vivian A. Fonseca: Hyperhomocysteinemia in Type 2 Diabetes: Cardiovascular risk factors and effect of treatment and folic acid and pyridoxine: Endoc Pract. 2000; 6:435-441
3. Uribarri J. Peppia, M. Cai W. Goldberyt., Lu M. **Baliga S.**, Vassalotti JA, Vlassara H. Dietary Glycotoxins Correlated with Circulating Advanced Glycation and Product Levels in Renal Failure Patients. Am J Kidney Dis. 2003 Sept; 42(3): 532-8
4. Goldberg T., Cai W, Peppia M., Dardaine V., **Baliga, B.S.**, Uribarri J., Vlassara H.: Advanced Glycooxidation End Products in Commonly Consumed Foods. J Am Diet Assoc. 2004 Aug; 104(8): 1287-91
5. Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes November 2020. BMJ Open Diabetes Research & Care 8(2):e001832 Authors: Pablo Mora, David R Sutton, Adhwini Gore, Bantwal Baliga
6. Diabetes and Stroke: Part one-risk factors and pathophysiology, Curr Cardiol Rep 2006 Feb;8.doi:10.1007/s11886-006-0006-0006-Bantwal Suresh Baliga, Jesse Weinberger

---

### PUBLICATIONS:

#### Invited Contributions:

- **Baliga, B.S.**, Fonseca, V. Recent Advances in the Treatment of Non-insulin Dependent Diabetes Mellitus. American Family Physician 55 (3): 817-824, 1997.
- Mark Grandberry, **Suresh Baliga**, and Vivian Fonseca: Clinical Pathophysiology of Painful Diabetic Neuropathy. Practical Diabetology. June 1999: 6-10.

#### Manuscripts Submitted:

Elevated Foxol Production Induces Hepatic Insulin Resistance

Jennifer Altomonte, Anja Richter, **Suresh Baliga**, Sonal Barbaran, Keying Song, Marcia Meseck, and H. Henry Dong. 2004

Book Chapter:

Nutritional Strategies for the Diabetic and Pre-diabetic Patient by **Bantwal Suresh Baliga** and Sachary Bloomgarden edited by Drs. Mechanick and Brett. 2004

#### Poster Presentations:

1. Refractory Hypothyroidism in a Young patient: Endocrine Society Meeting 2014
2. A case of Refractory Hypothyroidism which responded only to IV Levothyroxine due to selective malabsorption of Oral levothyroxine.: Endocrine Society meeting 2013
3. The First Real-World Experience with Bigfoot Unity-A Three-Month Retrospective Analysis Bantwal Baliga, et al. May 14, 2022. AACE annual meeting. San Diego
4. The First Real-World Experience with Bigfoot Unity-A Three-Month Retrospective Analysis Bantwal Baliga, et al. ADA 2022 - Poster session, New Orleans.
5. The First Real World Experience with Bigfoot Unity: A Six-Month Retrospective Analysis" with tracking number BALI2124D has been accepted as a virtual poster at the Diabetes Technology Meeting November 2022

#### Abstracts:

Foxo 1 Plays a role in Mediating the Effect of Fibrates on Diabetic Dyslipidemia:

Jennifer Altomonte, Karen Anthony, PhD, Suresh Baliga, M.D., Jing Xu, and Hengjiaing Dong, PhD, Present as an abstract for 2004 ADA Scientific Sessions, Orlando, FL.

#### Thesis Submitted:

"Value of Mantoux Test in Adult Tuberculosis: submitted to Mangalore University.

## CURRICULUM VITAE

**BANTWAL SURESH  
BALIGA, M.D.,  
M.R.C.P. (U.K.)**

---

### INVITED LECTURED/PRESENTATIONS:

1. Diabetic Emergencies: Little Rock Critical Care Program – Renal/Endocrine Module 4/09-1996
2. Recent Advances in the Treatment of Diabetes Mellitus: Endocrinology Grand rounds, UAMS, Little Rock, AR, Nov. 1995
3. Thyroid Hormone Resistance: Grand Rounds, VA Hospital, Little Rock, AR, Jan 1996
4. Modern Strategies in Treating Diabetes: Doctors Association Meeting, Bantwal, India, Dec. 2000
5. Homocysteine and Type 2 Diabetes, Workshop Presentation: Division of Diabetes and Aging, Mt. Sinai School of Medicine, March 2000
6. What Role Do Advanced Glycation End products Play in the Pathogenesis of Type 2 Diabetes: Diabetes Grand rounds, Mt. Sinai School of Medicine, March 2002
7. New Strategies in the Treatment of Type 2 Diabetes: Endocrinology Grand Rounds, Mt Sinai School of Medicine, April 2002
8. ALT-711 – Novel AGE Breaker, Endocrinology Journal Club, Mt. Sinai School of Medicine
9. Inhaled Insulins and Pulmonary Effects: Diabetes Grand rounds, Mt. Sinai School of Medicine, October 2003
10. What is new in Type 2 diabetes: NAKA Convention: Atlanta July 1, 2016
11. Management of Type 2 Diabetes: Corporate Seminar, Mt. Sinai School of Medicine, December 9, 2003
12. New Strategies in the Treatment of Type 2 Diabetes: Medicine Grand Rounds, Mount Vernon Hospital, New York, December 17, 2003

---

### MEDIA RESOURCE/EDUCATIONAL MATERIALS:

- Developed website for Diabetes Center at Mount Sinai, NY
  - Developed and initiated “Columbus Subcutaneous Insulin Protocol” for inpatient glycemic control at St. Francis Hospital, Columbus, GA
  - Helped establishing inpatient glycemic protocol for The Columbus Regional Medical Center, Columbus, GA
  - Regular contributor to TV talk show: “Straight forward with Gloria Strobe”
  - TV Show: “ Focus on Health”. With Claormont : “Pops” Barnes: Technological advances in diabetes and remote patient monitoring. September 15th 2022
  - Product Theater Presentation: Bigfoot in the wild: a real world experience. ADA conference in New Orleans, June 6, 2022
  - Addressing The Unmet Needs of Patients On Multiple Daily Injections Of Insulin Sponsored By Bigfoot Biomedical
- Product Theater Presentation:** AACE Annual Conference, San Diego. Saturday, May 14, 2022  
Presenter(s): Bantwal S. Baliga, MD: Ellen Ospelt, RN, BS, CDCES: Jeffrey Brewer CEO, Bigfoot Biomedical
- Global Webinar: Utilizing Remote Patient Monitoring with Continuous Glucose Monitoring: Care from across the globe : with Dr Subodh Agrawak, 8-25-22
  - Podcast: The First Real-World Experience with Bigfoot Unity–A Three-Month Retrospective Analysis  
On mefyle.com. Podcast by Bantwal Baliga , PRESENTING AUTHOR

### CGMS Experience:

- : One of the first physicians to initiate Clinical integration of CGMS in Columbus, GA and Opelika, AL
- : First Physician to use Medtronic 670 G insulin pump with threshold suspend in Alabama.
- : First in the country to insert first implantable CGMS- Eversense in Columbus, GA
- : Key note speech on sensors and sensor augmented pump technology at the national AAPI conference in Atlanta on July 3rd 2019.
- : Sensors and sensor augmented pump technology speech to GAPI, in Columbus, GA in September, 2019

### Press Mentions:

- Bigfoot Unity® Demonstrates Strong Glycemic Control Among People with Type 2 Diabetes in Real-World Retrospective Analysis  
June 5, 2022  
Yahoo Finance

Senseonics Announces the First Patient Implant of the Eversense E3 CGM System in the U.S. April 7th, 2022

Bigfoot Clinic Hub™ Puts Critical Data at Fingertips of Health Care Professionals to Enable Proactive Care of Their Patient Populations with Type 1 and Type 2 Diabetes. December 2nd, 2021